Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary-care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins
- PMID: 34953089
- DOI: 10.1111/myc.13419
Molecular characterisation of Candida auris isolates from immunocompromised patients in a tertiary-care hospital in Kuwait reveals a novel mutation in FKS1 conferring reduced susceptibility to echinocandins
Abstract
Background: Candida auris is an emerging, potentially multidrug-resistant pathogen that exhibits clade-specific resistance to fluconazole and also develops resistance to echinocandins and amphotericin B easily. This study analysed 49 C auris isolates for alterations in hotspot-1 and hotspot-2 of FKS1 for the detection of mutations conferring reduced susceptibility to echinocandins.
Methods: C auris isolates (n = 49) obtained from 18 immunocompromised patients during June 2016-December 2018 were analysed. Antifungal susceptibility testing was performed by Etest and broth microdilution-based MICRONAUT-AM assay. Mutations in hotspot-1 and hotspot-2 regions of FKS1 were detected by PCR sequencing and fingerprinting of the isolates was done by short tandem repeat typing.
Results: The patients had multiple comorbidities/risk factors for Candida spp. infection including cancer/leukaemia/lymphoma/myeloma (n = 16), arterial/central line (n = 17), urinary catheter (n = 17), mechanical ventilation (n = 14) and major surgery (n = 9) and received antifungal drugs as prophylaxis and/or empiric treatment. Seven patients developed C auris candidemia/breakthrough candidemia, nine patients had candiduria with/without candidemia and four patients developed surgical site/respiratory infection. Resistance to fluconazole and amphotericin B was detected in 44 and four isolates, respectively. Twelve C auris isolates from eight patients showed reduced susceptibility to echinocandins. Seven isolates contained hostspot-1 mutations and three isolates from a candidemia patient contained R1354H mutation in hotspot-2 of FKS1. Ten patients died, five were cured, two were lost to follow-up and treatment details for one patient were not available.
Conclusions: Our findings describe development of a novel mutation in FKS1 conferring reduced susceptibility to echinocandins in one patient during treatment and unfavourable clinical outcome for many C auris-infected patients.
Keywords: C auris; Immunocompromised patients; breakthrough candidemia; echinocandin resistance; hotspot-2 FKS1 mutation; infection.
© 2021 Wiley-VCH GmbH.
Similar articles
-
A benchmark dataset for validating FKS1 mutations in Candida auris.Microbiol Spectr. 2025 Aug 5;13(8):e0314724. doi: 10.1128/spectrum.03147-24. Epub 2025 Jun 18. Microbiol Spectr. 2025. PMID: 40530813 Free PMC article.
-
Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.Sci Rep. 2020 Apr 10;10(1):6238. doi: 10.1038/s41598-020-63240-z. Sci Rep. 2020. PMID: 32277126 Free PMC article.
-
Fatal Breakthrough Candidemia in an Immunocompromised Patient in Kuwait Due to Candida auris Exhibiting Reduced Susceptibility to Echinocandins and Carrying a Novel Mutation in Hotspot-1 of FKS1.J Fungi (Basel). 2022 Mar 6;8(3):267. doi: 10.3390/jof8030267. J Fungi (Basel). 2022. PMID: 35330269 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.Dan Med J. 2016 Oct;63(10):B5288. Dan Med J. 2016. PMID: 27697142 Review.
Cited by
-
Spectrum and management of rare Candida/yeast infections in Kuwait in the Middle East.Ther Adv Infect Dis. 2024 Jul 24;11:20499361241263733. doi: 10.1177/20499361241263733. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 39070702 Free PMC article. Review.
-
Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of Candida auris: Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest.Antibiotics (Basel). 2024 Sep 4;13(9):840. doi: 10.3390/antibiotics13090840. Antibiotics (Basel). 2024. PMID: 39335013 Free PMC article.
-
Molecular mechanisms governing antifungal drug resistance.NPJ Antimicrob Resist. 2023;1(1):5. doi: 10.1038/s44259-023-00007-2. Epub 2023 Jul 17. NPJ Antimicrob Resist. 2023. PMID: 38686214 Free PMC article. Review.
-
Genomics insights of candidiasis: mechanisms of pathogenicity and drug resistance.Front Microbiol. 2025 Feb 27;16:1531543. doi: 10.3389/fmicb.2025.1531543. eCollection 2025. Front Microbiol. 2025. PMID: 40083780 Free PMC article. Review.
-
Candida auris: A Mini Review on Epidemiology in Healthcare Facilities in Asia.J Fungi (Basel). 2022 Oct 26;8(11):1126. doi: 10.3390/jof8111126. J Fungi (Basel). 2022. PMID: 36354893 Free PMC article. Review.
References
REFERENCES
-
- Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14:5-24.
-
- Sprute R, Cornely OA, Chen SC, Seidel D, Schuetz AN, Zhang SX. All you need to know and more about the diagnosis and management of rare yeast infections. MBio. 2021;12:e0159421.
-
- Calley JL, Warris A. Recognition and diagnosis of invasive fungal infections in neonates. J Infect. 2017;74:S108-S113.
-
- McCarty TP, Pappas PG. Invasive candidiasis. Infect Dis Clin North Am. 2016;30:103-124.
-
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-e50.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous